James Openshaw

Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom.

Chelsea Avondale Ltd. has developed Skynet, a precision risk technology for property and casualty insurance. The company is based in Hamilton, Bermuda and has subsidiaries in Barbados. Skynet was created by going back to the scientific principles that cause insurance claims. The first implementation of Skynet was completed in Chelsea Avondale's wholly owned Bermudian insurance company, Max Insurance. Chelsea Avondale believes that scientific underwriting is the future of insurance. The company was founded by Gregory H. Bailey and the CEO is Nilesh Mukundrai G. Vasani.

Mediqventures Ltd. provides financing services for life science technologies. The private company is based in Douglas, UK. The British company was founded by Gregory H. Bailey.

LyGenesis, Inc. operates as a biotechnology company. It develops an organ regeneration technology platform enabling a patient's lymph nodes to be used as bioreactors to regrow functioning ectopic organs. The company is headquartered in Pittsburgh, PA.

Part of Ernst & Young Global Ltd., Arthur Andersen (UK) is a British company that provides accounting services. The company is based in Reading, UK.

Cambridge Cognition Ltd. operates as a neuroscience technology company delivering near-patient assessment solutions to improve the understanding, diagnosis and treatment of neurological and psychiatric disorders. It offers CANTAB Tests and Services, CANTAB mobile and CANTABeclipse. The company was founded in 2002 and is headquartered in Cambridge, GB.

Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom.

Gilde Healthcare Partners BV is a Private Equity/Venture Capital firm, a subsidiary of Gilde Healthcare Holding BV founded in 1999 by Pieter van der Meer and Edwin William de Graaf. Gilde Healthcare Partners BV is headquartered in Utrecht with additional office in Cambridge.

Excalibur Fund Managers Ltd (Excalibur) is a venture capital firm founded in 1996 by Christopher Evans. The firm is headquartered in London, United Kingdom.

eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.

Macrotarg Ltd. is a biotechnology research and British experimental development company founded in 2007. The private company is based in Winnersh, UK.

The Native Antigen Co. Ltd. develops viral vectors technologies. Its products include bacterial antigens, protozoal, and viral antigens. The company was founded by Nick Roesen and Andrew Maxwell in 2010 and is headquartered in Oxford, the United Kingdom.

Part of Ferring Holding SA, FKD Therapies Oy is a Finnish pharmaceutical company that manufactures and markets products for cancer treatment. The company is based in Kuopio, Finland. FKD Therapies was acquired by Ferring International Center SA on June 01, 2014.

Part of Ferring Holding SA, Finvector Vision Therapies Ltd. is a British pharmaceutical company that manufactures and markets products for cancer treatment. The company is based in Chinnor, UK. Finvector Vision Therapies was acquired by Ferring International Center SA on June 01, 2014.

Trizell Ltd. engages in research and experimental development on biotechnology. The company was founded on April 14, 1997 and is headquartered in Chinnor, the United Kingdom.

Part of GSK Plc, GSK International Ltd. operates a travel agency. The company is based in Ilford, UK.

Radiometer A/S develops as well as manufactures blood gas instruments and support devices. It supplies blood gas analyzers that measure blood gases and other parameters used to diagnose critically ill patients. It also provides accessories, IT systems and support services for blood gas testing, besides producing instruments that measure blood gases transcutaneously. The company consists of three subsidiaries Radiometer Medical ApS (Denmark), SenDx Medical, Inc. (US) and Radiometer Basel AG (Switzerland). Radiometer was founded in 1935 and is headquartered in Br?nsh?j, Denmark.

Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom.

Gilde Investment Management BV is an Independent Private Equity firm founded in 1982. Gilde Investment Management BV is headquartered in Utrecht.

Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom.

Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA.

Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom.